Eiger BioPharmaceuticals Profit Margin

As of the most recent data (December 2023), EIGRQ shows a profit margin of -475.26%. That compares with -717.71% in the prior-year period — up 33.8% year over year. That is below the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EIGRQ's profit margin is now -475.26% (was -717.71%) — a 33.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Eiger BioPharmaceuticals is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. Eiger BioPharmaceuticals is at -475.26%, which is lower that average. That is roughly 3413.1% below the sector mean. Use the comparison chart on this page to see how EIGRQ stacks up against individual peers as well.

That compares with -717.71% in the prior-year period — up 33.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Eiger BioPharmaceuticals with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Eiger BioPharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -475.26%) with ownership activity and broader fundamentals.